Compare GITS & ACON Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GITS | ACON |
|---|---|---|
| Founded | 2018 | 2008 |
| Country | South Korea | United States |
| Employees | 5 | N/A |
| Industry | | Retail: Computer Software & Peripheral Equipment |
| Sector | | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.3M | 7.4M |
| IPO Year | N/A | 2022 |
| Metric | GITS | ACON |
|---|---|---|
| Price | $1.85 | $2.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | ★ 103.0K | 45.6K |
| Earning Date | 05-19-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 99.82 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $75,730.00 |
| Revenue This Year | N/A | $87.22 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 65.62 |
| 52 Week Low | $0.66 | $1.95 |
| 52 Week High | $7.09 | $12.03 |
| Indicator | GITS | ACON |
|---|---|---|
| Relative Strength Index (RSI) | 44.90 | 52.82 |
| Support Level | $1.19 | $2.38 |
| Resistance Level | $2.42 | $3.54 |
| Average True Range (ATR) | 0.28 | 0.16 |
| MACD | -0.04 | 0.05 |
| Stochastic Oscillator | 11.48 | 87.69 |
Global Interactive Technologies Inc is operating and developing Faning, a digital fan engagement platform focused on Korean entertainment and culture, including K-pop. Faning is designed to support online fan communities, user interaction, multilingual communication, and digital engagement experiences across mobile and web-based services. The platform evolved from the legacy Fantoo platform ecosystem. The Company's primary operational focus was the continued development, maintenance, and support of the Faning platform. The Company operates its business through its core Faning platform and strategy.
Aclarion Inc is a healthcare technology company that leverages Magnetic Resonance Spectroscopy (MRS), proprietary signal processing techniques, biomarkers, and augmented intelligence algorithms to optimize clinical treatments. The Company is first addressing the chronic low back pain market with Nociscan. Through a cloud connection, Nociscan receives magnetic resonance spectroscopy (MRS) data from an MRI machine for each lumbar disc being evaluated. In the cloud, proprietary signal processing techniques extract and quantify chemical biomarkers demonstrated to be associated with disc pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.